A systematic comparison of optogenetic approaches to visual restoration

Michael J. Gilhooley,1,2,3,4 Moritz Lindner,1,2,5 Teele Palumaa,2,6 Steven Hughes,1,2 Stuart N. Peirson,1,2 and Mark W. Hankins1,2

During inherited retinal degenerations (IRDs), vision is lost due to photoreceptor cell death; however, a range of optogenetic tools have been shown to restore light responses in animal models. Restored response characteristics vary between tools and the neuronal cell population to which they are delivered: the interplay between these is complex, but targeting upstream neurons (such as retinal bipolar cells) may provide functional benefit by retaining intraretinal signal processing. In this study, our aim was to compare two optogenetic tools: mammalian melanopsin (hOPN4) and microbial red-shifted channelrhodopsin (ReaChR) expressed within two subpopulations of surviving cells in a degenerate retina. Intravitreal adeno-associated viral vectors and mouse models utilising the Cre/lox system restricted expression to populations dominated by bipolar cells or retinal ganglion cells and was compared with non-targeted delivery using the chicken beta actin (CBA) promoter. In summary, we found bipolar-targeted optogenetic tools produced faster kinetics and flatter intensity-response relationships compared with non-targeted or retinal-ganglion-cell-targeted hOPN4. Hence, optogenetic tools of both mammalian and microbial origins show advantages when targeted to bipolar cells. This demonstrates the advantage of bipolar-cell-targeted optogenetics for vision restoration in IRDs. We therefore developed a bipolar-cell-specific gene delivery system employing a compressed promoter with the potential for clinical translation.

INTRODUCTION

Inherited retinal degenerations (IRDs) represent one of the largest causes of visual morbidity in the working age population, affecting around 1 in 4,000 people.1 Vision is ultimately lost in these conditions through a final common pathway of photoreceptor loss, driven by a mutation in one of hundreds of different genes known to cause IRDs.1 The development of a clinical retinal gene replacement therapy based on an adeno-associated viral (AAV) delivery system2 has heightened the drive to develop mutation-independent approaches to restoring vision, which may be applicable even after photoreceptors are lost. Optogenetics, the introduction of transgenic protein tools rendering targeted cells photosensitive, has been demonstrated in preclinical models to restore light responses using a variety of optogenetic tools3–15 and has entered early-phase clinical trials (ClinicalTrials.gov: NCT02556736 and NCT03326336; clinicaltrials.gov). Indeed, Sahel et al.16 recently provided the first description of human visual responses being restored using an optogenetic approach with the case report16 of a participant in the PIONEER study. In this phase I/II study, an optogenetic tool (Chrimson R) is delivered using intravitreal injection of AAV into patients with end-stage IRD. Following treatment, the patient was able to perform visually guided tasks with occipital electroencephalograms (EEGs) recorded in response to visual stimuli. The full results of this clinical trial are still to be published at the time of writing.

This trial illustrates two important choices that must be made in designing an optogenetic therapeutic: the first is what tool to use? In PIONEER, Chrimson R was employed due to its advantageous spectral sensitivity and the fact it is only active above ambient-light intensities (a useful safety feature for early clinical trials as it is not constitutively active). This, however, requires cumbersome amplifying googles, so it may not be foremost for therapeutic translation in the longer term.

The second choice is which cell types should the tool be targeted to? In PIONEER, a high efficiency, non-specific (CAG) promoter is used with the aim of expressing good quantities of optogenetic tool in as many cell types as possible (ensuring as high a magnitude light response as possible). However, reports in animal models have emerged demonstrating that useful intraretinal signaling processing can be retained when upstream retinal neurons are targeted specifically: in particular, that ON- and OFF-type responses can be restored when upstream retinal neurons are targeted specifically. This, however, requires cumbersome amplifying googles, so it may not be foremost for therapeutic translation in the longer term.

Received 16 December 2021; accepted 4 March 2022; https://doi.org/10.1016/j.omtm.2022.03.003.

Correspondence: Mark W. Hankins, Nuffield Laboratory of Ophthalmology, Nuffield Department of Clinical Neuroscience, University of Oxford, Oxford OX1 3QU, UK.

E-mail: mark.hankins@eye.ox.ac.uk
A) Non-targeted vs. Targeted

B) Overview

C) INL

D) GCL

E) Cross section

F) INL cells stained

G) GCL cells stained

(legend on next page)
tool will function, and it is this combination that will ultimately define suitability for optogenetic therapy.

To date, only a very small number of studies have directly compared candidate optogenetic tools, and none have systematically addressed the role of the different classes of optogenetic tools and target cell populations in the same model system.5,3–4,20–23 In addition, none have compared responses in a degenerate model devoid of both rod, cone, and melanopsin responses22,24 to remove the confounder of residual native light responses.

With this small number of directly comparative studies, many of the relative advantages and disadvantages of particular optogenetic tools remain somewhat theoretical in relation to IRDs. The aim of this study is to directly compare the sensitivity and kinetics of two leading tools, namely human melanopsin (hOPN4)6,25,26 and the red-shifted channelrhodopsin ReaChR,10 when expressed either non-specifically or within relatively defined subpopulations of surviving cells in the degenerate retina. These two tools were chosen as reasonably well-characterized examples (at both the physiological and behavioral levels) of the two main classes of optogenetic tools: mammalian opsins (hOPN4) and microbial ion channels (ReaChR). The promoter constructs (chicken beta actin [CBA; non-specific], L7 [ON bipolar cell dominant], Grik4 [retinal ganglion cell dominant]) were chosen as examples where the cell populations they target are well described in various contexts. As both comparisons indicated a functional advantage to targeting populations rich in upstream neurons, we proceeded to develop a clinically translatable promoter targeted gene delivery strategy enabling optogenetic tool expression in the ON bipolar cell population.

RESULTS

Comparing sensitivity and kinetics of hOPN4 when targeted non-specifically and to L7 and Grik4 subpopulations of retinal cells as an optogenetic tool

Restricting expression to defined subpopulations using the Cre/lox system

Ongoing clinical trials employ a transduction strategy to broadly express optogenetic tools in multiple surviving neuronal cell types (ClinicalTrials.gov: NCT04945772, NCT02556736 NCT04919473, and NCT03326336; clinicaltrials.gov). To replicate this, we employed AAV (AAV2/2 quad mutant Y272,444,500,730F) to deliver hOPN4 driven by a high efficiency, non-specific promoter (CBA) via intravitreal injection (Figure 1A). Consistent with previous reports,8 this achieved expression of hOPN4 protein throughout the mouse retina, with preferential expression in horizontal cells and retinal ganglion cells (Figures 1B–1G), hereafter referred to as CBA.hOPN4. In order to directly compare this non-specific delivery, a modified AAV construct incorporating a floxed hOPN4 gene (flox.hOPN4) (Figure 1A) was used to restrict expression only to cells expressing the Cre recombinase enzyme in our transgenic mouse models.

When flox.hOPN4 was administered to the Grik4.Cre mouse (Grik4.hOPN4), protein staining was seen in a subset of retinal ganglion cells (RGCs) as previously described.27 When the flox.hOPN4 virus was administered to the L7.cre mice (L7.hOPN4), staining was seen within a proportion of L7-expressing bipolar cells,28 of the inner nuclear layer (Figures 1C and 1F) together with a small subpopulation of RGCs, as previously described27 (Figures 1D and 1G).

Targeting hOPN4 to defined subpopulations of cells evokes distinct response characteristics

Eight weeks after intravitreal injection, CBA.hOPN4, L7.hOPN4, and Grik4.hOPN4 mice were culled for ex vivo multiple-electrode array (MEA) electrophysiological recordings. In all three treatment groups, exogenously expressed hOPN4 protein was able to drive changes in spike firing of RGCs in response to light; there were no such changes in saline control groups, confirming the absence of native melanopsin responses (Figures 2A and 2B). While hOPN4-treated groups had significantly more light-responsive electrodes than saline groups (one way ANOVA, $F_{(3,21)} = 4.136; p < 0.0188$ with Tukey’s post hoc test), there were no significant differences in the proportion of light-responsive electrodes between treatment groups (Figure 2C).

The half-life ($t_{1/2}$) of light responses provides an overarching index of decay kinetics in each group. This value lengthened with stimulus intensity ($F_{(6,2116)} = 137.2; p < 0.0001$) and varied between treatment groups ($F_{(2,2116)} = 29.68; p < 0.0001$). This suggests that while brighter stimuli led to generally longer $t_{1/2}$, decay kinetics were significantly shortened when hOPN4 was targeted to L7-positive ON bipolar cells compared with RGCs or non-specific delivery (see Figure 2D for post hoc test).

Irradiance response curves (IRCs; Figure 2E) revealed that there was no significant difference in the half maximal effective concentration (EC50) between CBA.hOPN4 (13.74 ± 0.11 log10 photons cm$^{-2}$ s$^{-1}$) and L7.hOPN4 (13.64 ± 0.21 log10 photons cm$^{-2}$ s$^{-1}$) (one-way ANOVA $F_{(2,109)} = 18.31; p < 0.0001$; Tukey’s post hoc test; $p = 0.8053$), while...
Grik4.hOPN4 (13.03 ± 0.06 log10 photons cm^-2 s^-1) was significantly more sensitive than hOPN4 delivered either non-specifically or to L7 ON bipolar cells (Tukey’s post hoc test; p < 0.0005 for both comparisons). The Hill slope of a sigmoidal IRC provides a measure of the range of light intensities the modeled opsin is able to encode (i.e., its dynamic range). With L7.hOPN4, the Hill slope was significantly lower than for hOPN4 delivered non-specifically or targeted to RGCs (one-way ANOVA F(2,109) = 6.853; p < 0.0001; Tukey’s post hoc test; p < 0.01 for both comparisons). The dynamic range of hOPN4 is approximately two orders of magnitude when expressed in RGCs or non-specifically but extends over five orders of magnitude when expressed in L7-positive ON bipolar cells, a very significant difference when considering clinical translation. Both this advantage in dynamic range with L7-positive bipolar cell targeting and in absolute sensitivity with Grik4-positive RGC targeting could be explained by differences either in the signaling cascade dynamics within the transduced cells or their connections to other cells (e.g., the retention of an additional synaptic layer with L7-positive bipolar targeting allowing integration of overlapping individual bipolar cell ranges).

Comparing targeted delivery of receptor- and channel-based optogenetic tools

We next sought to investigate if these differences in kinetics and sensitivity of response were dependant on the tool used or if they were attributable to features intrinsic to the targeted cell population (and therefore expandable to distinct classes of optogenetic tools). We
Figure 3. Targeted hOPN4 and ReaChR delivery

(A) Insert plasmid used to make flox.ReaChR vector. Inverted sequences are shown upside down. (B) IHC showing expression of ReaChR.mCitrine. Please note that GFP antibody cross-reacts with mCitrine in flox.ReaChR construct, hence its use here. An additional saline control (not shown) was stained for GFP with appearances similar to that stained for hOPN4 in Figure 1. Scale bars: whole retina, 500 μm; otherwise, 20 μm. (C) Proportion of all cells staining for GFP in the INL and GCL. Each point is the mean value taken over four 40× fields of view (n = 4) from one animal (N = 4). GCL: one-way ANOVA F(1.297,3.890) = 19.24, p < 0.0113; Tukey’s post hoc test: L7.ReaChR versus

(legend continued on next page)
addressed this question by repeating the same set of experiments using a structurally and functionally unrelated optogenetic tool as a control. ReaChR\(^{(16)}\) is a photoactivated ion channel and so, unlike hOPN4 (a G-protein coupled receptor), does not couple to an amplifying second-messenger cascade and thus is expected to produce less sensitive responses but with faster kinetics.

Delivery of a floxed ReaChR construct (Figure 3A) resulted in cell-specific expression of ReaChR protein in both L7.Cre and Grik4.Cre mice (Figures 3B and 3C). As with hOPN4, expression of ReaChR was able to drive light responses (Figures 3D and 3E). However, the mean baseline (10 s pre-stimulus) F(3,28) = 11.61; p < 0.0001), but there was no difference in the proportion (two-way ANOVA F(63,407) = 14.81; p < 0.0001) and varied with treatment group (F (33,407) = 107.1; p < 0.0001). Again, as expected,\(^6,10,20\) brighter stimuli led to longer \(t_{1/2}\), but decay kinetics were faster in ReaChR compared with hOPN4-treated groups, especially in the Grik4.ReaChR group at higher intensities (Figure 3I). Spike adaptation (measured as the \(t_{1/2}\) of responses from the point of maximum spike firing to that of stimulus offset) was not significantly different between groups (Kruskal-Wallis [KW] test, KW statistic = 3.181, p = 0.3646). Full offset kinetics (the \(t_{1/2}\) of responses from the point of response offset) varied between groups (KW test, KW statistic = 38.07, p < 0.0001); however, Dunn’s post hoc test was only significant for comparisons between groups, not target cell populations (L7.hOPN4: 11.82 ± 1.84 s; L7.ReaChR: 3.143 ± 0.50 s; Grik4.hOPN4: 10.43 ± 0.99 s; Grik4.ReaChR: 3.86 ± 0.83 s).

Again, a sigmoidal irradiance response relationship could be observed for both conditions (Figure 3J). There was no significant difference in \(EC_{50}\) between ReaChR groups, regardless of where the tool was targeted; ReaChR groups were less sensitive to light than hOPN4 when targeted to the same populations (KW test with Dunn’s post hoc test, KW statistic = 93.46, p < 0.0001; see Figure 3G for post hoc test values). Similarly, there were significant differences in the Hill slope between groups with a lower value when treatment was targeted to L7-positive ON bipolar cells as opposed to Grik4-positive RGCs, similar to that seen for hOPN4 (KW test with Dunn’s post hoc test; KW statistic = 61.93, p < 0.0001; see Figure 3K for post hoc values).

A compressed L7 promoter construct can be used to selectively express functional hOPN4 in ON bipolar cells, without the need for the Cre/lox system

There is an increasing body of evidence to suggest that intraretinal signal processing can be maintained by targeting surviving upstream retinal neurons, especially bipolar cells.\(^13,17-19,29\) The flatter stimulus intensity-response relationship and shorter decay time further support ON bipolar cells as favorable targets for optogenetic vision restoration. Despite recent advances,\(^30\) obtaining such targeted expression within bipolar cells remains challenging. The large size of the L7 promoter (2.9 kbp) precludes its integration with an opto-genetic tool within the c.5 kbp packaging capacity of an AAV.\(^31\)

Recently, a compressed L7 promoter (L7-6) has been developed and has proven efficient in both mice and primates.\(^32\) We hypothesized that such a promoter could be a valuable and clinically translatable tool to obtain specific expression of hOPN4 within L7-positive ON bipolar cells.

In a series of pilot experiments, we therefore constructed AAV carrying hOPN4 under the control of the L7-6 construct (L7-6.hOPN4; Figure 4A). Using immunocytochemistry, we confirmed that this vector was able to drive the production of human hOPN4 protein in L7-expressing bipolar cells in primary murine retinal cell culture. Based on these in vitro culture findings, we proceeded to intravitreally inject L7-6.hOPN4 into the eyes of 4-week-old retinal degenerate, melanopsin-deficient (Pdeo6brd/rd1 Opn4tm1yau/tm1yau) mice. Four weeks later, retinal tissue was collected for immunohistochemistry (IHC) showing staining for hOPN4 in cells located in the inner nuclear layer (INL) that also co-stained for L7 protein. A small number of cells in the ganglion cell layer (GCL) were stained, consistent with findings in the L7 Cre.lox model.\(^37\) Additionally, we confirmed that this approach results in the expression of functional hOPN4 and is able to drive changes in the spike firing rate of RGCs in responses to light (Figures 4B–4I). This light responsiveness was seen in a similar proportion of electrodes (Figure 4G) to that seen...
Figure 4. hOPN4 delivered using the L7-6 promoter  
(A) Insert plasmid used to make L7-6 hOPN4 vector. (B) IHC showing expression of L7-6 hOPN4. Scale bars: whole retina 250 μm; otherwise, 25 μm. (C) Example raw recording traces from a single electrode in each treatment group stimulated with a 10 s pulse of 480 nm, 10^{14} photons cm^{-2} s^{-1} light (blue bar). (D) Mean change in spike firing rate from all responsive electrodes in each group in response to a 10 s pulse of 480 nm, 10^{14} photons cm^{-2} s^{-1} light (yellow shading). (E) Proportion of L7-expressing cultured primary dissociated mouse retina cells incubated with L7-6 hOPN4 AAV that also express Opn4. Treatment groups, n = 197 total L7 cells; saline, n = 213 cells (unpaired t test p < 0.0010). (F) Whole retina IHC: cells staining for hOPN4 in the GCL and INL (as a proportion of all cells) compared with the proportion of cells staining for hOPN4 as well as L7 in the INL. N = 4 retinas each. (G) The proportion of electrodes scored as responsive. N = 4 retinas, n = 32 electrodes. (H) Response decay kinetics: the time taken from maximum response to t_{1/2}. (I) IRCs were plotted using the mean EC_{50}, and Hill slope values were derived from averaging those of individual electrode fits. L7-6 hOPN4: EC_{50} 13.27 ± 0.09 photons cm^{-2} s^{-1}; Hill slope 1.21 ± 0.11, r^2 = 0.9380 ± 0.009, n = 31. GCL, ganglion cell layer; INL, inner nuclear layer; ITR, inverted terminal repeat; L7-6, L7-6 promoter; hOPN4, human melanopsin gene; WPRE, Woodchuck hepatitis virus post transcriptional regulatory element; PolyA, Poly(A) tail. Unless otherwise indicated, data is presented as mean ± standard error of the mean.
with Cre-lox-mediated delivery, with a peak $t_{1/2}$ around $10^{14}$ photons cm$^{-2}$ s$^{-1}$ (Figure 4H), and fitted a sigmoidal irradiance response relationship with an EC$_{50}$ of $13.27 \pm 0.09$ photons cm$^{-2}$ s$^{-1}$ (Figure 4I).

**DISCUSSION**
In this study, we describe a direct comparison of the optogenetic tool hOPN4 expressed non-specifically and within defined subpopulations of the degenerate retina. We show that targeting different cell groups markedly alters the reconstituted light responses. Furthermore, we demonstrate the use of the compressed L7-6 promoter construct to deliver a gene (hOPN4) specifically to a population rich in retinal ON bipolar cells, a technique that could potentially allow direct clinical translation of this work.

**Subpopulation targeting of hOPN4 produces differing response characteristics**
While the wider dynamic range seen when either tool was targeted to L7-positive ON bipolar cells is potentially useful for clinical translation of the technique, it may have been expected given the additional synaptic layer retained allowing the integration of overlapping ranges of upstream bipolar cells. However, the markedly increased absolute sensitivity seen when RGCs were targeted with melanopsin could also have utility in providing perception in lower-light conditions. Several factors could contribute to these differences in sensitivity and dynamic range including the network interactions and intrinsic neurophysiological properties of this cell population, e.g., lower membrane resting potential, and these may change depending on the exact capsid, promoter construct, and tool employed.

However, in our comparison, the observation that increased sensitivity of hOPN4 was not replicated when ReaChR was similarly targeted may also be explained by melanopsin coupling to an alternative second-messenger system in RGCs compared with ON bipolar cells. Melanopsin is reported to couple to different G protein systems in vitro$^{33,34}$ and in vivo$^{35–37}$ depending on the cellular environment in which it is expressed. As a $G_{q/11}$-coupled G protein, natively expressed in a subtype of RGC, melanopsin may indeed find a preferred cascade to couple to when expressed in RGCs, increasing sensitivity when compared with bipolar cells where $G_{q/11}$ signaling is less prominent. Differential coupling may also be important in explaining the expedited decay kinetics seen when melanopsin is expressed in the L7-positive ON bipolar cell population. In its native cell (the intrinsically photosensitive RGC), hOPN4 has been proposed to have its response terminated by activity-dependent phosphorylation of a region of its C terminus$^{38–42}$ which allows arrestin-B2$^{33,43–47}$ to bind. The presence of cell-specific kinases in L7-positive bipolar cells, e.g., protein kinase C alpha (PKCz)46 central to the termination the ON bipolar native light response$^{47–51}$ may represent a potential mechanism if PKCz were able to facilitate this phosphorylation of melanopsin. Indeed, further investigation of hOPN4 coupling and response termination in ON bipolar cells could provide a fruitful avenue of investigation to further optimize its sensitivity and kinetics for therapeutic use.

**Comparing targeted delivery of two candidate optogenetic tools**

**Baseline firing**
Key differences between mammalian and microbial opsins, in particular sensitivity and kinetic behaviors, have been extensively discussed.$^{14,59}$ Yet, the functional differences we observed comparing these tools in the context of our comparison extended beyond this: in particular, the higher baseline firing rates seen in all ReaChR groups compared with hOPN4. Changes in baseline firing have been noted in optogenetically treated rd1 retina previously.$^{52}$ Indeed, in vitro studies have suggested a small amount of leak current is present with exogenously expressed channelrhodopsins, allowing ingress of cations (notably Ca$^{2+}$) with repeated activation.$^{53,54}$ This could presumably lead to a slight, relative depolarization of the membrane potential, so accounting for both an increased spontaneous baseline and higher post stimulus spike firing rate in these groups. The potential long-term toxicity of a leak current to retinal neurons specifically has not been investigated, but there are suggestions of channelrhodopsins causing toxicity in other tissues.$^{55,56}$ While more detailed characterization of increased baseline firing is indicated as these tools move toward the clinic, in this study, it does not appear to impair cells’ ability to respond to light stimuli with spike trains or, indeed, significantly alter the proportion of responsive electrodes.

**Sensitivity and kinetics**
Indeed, in the move toward translation, the lower sensitivity of microbial tools (such as ChannelRhodopsin2 [ChR2]57) has been cited as a disadvantage, with extraocular amplification equipment often required.$^{13}$ While the absolute levels of sensitivity with ReaChR seen here are higher with targeted delivery, in this study, they are not yet comparable to hOPN4 deployed to the same cell population. Additionally, ReaChR groups demonstrated narrower dynamic ranges than hOPN4 ones, likely a combination of both high open probabilities of individual channels$^{58}$ and the lack of second-messenger coupling. Indeed, in terms of sensitivity and dynamic range, hOPN4 would appear to be the more attractive tool in both populations investigated here and compares favorably with other opsin tools on these metrics (when used for visual restoration, cone or rhodopsin required similar or even higher stimulus intensities).$^{3,5,59}$

However, the lower sensitivity of ReaChR is countered by the markedly expedited decay kinetics when it was targeted to either cell population in this study. This is additionally interesting in the context of previous observations that ReaChR is better able to track sinusoidal stimuli when targeted to an L7-positive bipolar population, compared with non-specific delivery.$^{13}$ These findings would imply a better temporal resolution and would warrant further development, given the need for such resolution for the restoration of naturalistic vision.

**Limitations**
In developing potential cell-population-specific optogenetic vision-restoration therapies, however, care must be taken when extrapolating findings as levels of protein expression in individual cells can vary depending on not only the capsid and promoter used but also...
the species and specific state of the retina, as well as the route of delivery and concentration of vector. Additionally, few promoter constructs are completely specific for a sole type of retinal cell.

Considering these limitations, we selected two Cre promoter constructs with relatively well-described off-target expression, integrated high-efficiency promoters (E12 and hSyn) into the AAVs, and injected “neat” (undiluted) vectors intravitreally to maximize expression. While this approach was chosen to maximize expression, we cannot exclude that our observations in this study may be partially biased by different transduction efficiencies caused by using different viral titers and promoters between targeted groups.

The Grik4 construct is known to restrict expression to a well-defined population of direction-sensitive RGCs and L7 mainly to retinal ON bipolar cells in mice (such as the widely used rd1 model of retinal degeneration employed here). However, in common with other bipolar-cell-targeting constructs (e.g., grm6-SV40), L7 has some off-target expression. For ease, throughout this report, these Grik4 and L7 populations have been referred to as RGCs and ON bipolar cells; however, this off-target expression must be considered when extrapolating conclusions to other situations.

Patterns of off-target expression and variable levels of protein expression between cells will be inherent to any combination of promoter and capsid. This will persist through to translation here we selected well-described transgenes, promoters, capsids, and models. This allowed us to represent the most relevant classes of tool and target populations - incorporating off-target effects and variability in quantity of expression to give a useful functional comparison for the first time. This will help to direct the future detailed comparisons required to replicate our findings with other promoter-capsid combinations and isolate individual cell responses.

Compressed promoter delivery of hOPN4
The targeting of retinal ON bipolar cells with specific promoters has several advantages for functional optogenetic vision restoration—not least the retention of an additional intraretinal synapse to retinal image processing. Moreover, we have recently shown that these cells undergo relatively little transcriptomic changes in the context of IRDs, making them an attractive target for optogenetic gene therapies despite retinal remodeling.

These advantages, together with the increased dynamic range and favorable response kinetics we observed when hOPN4 was targeted to the L7-positive bipolar cell population, led us to combine hOPN4 with a repurposed compressed (shortened) L7-6 promoter construct. One of the barriers to population-targeted gene therapies is the limitations in payload size of AAV vectors: many specific promoters (including L7) are too large to fit along with a transgene within the vector envelope. The L7-6.hOPN4 construct, delivered by AAV vector, was able to target functional hOPN4 to L7-positive bipolar cells in a degenerate retina without the need for the Cre/lox system. Indeed, further work is required to expand this preliminary investigation—for example, by using L7-6 to deliver alternative tools such as ReaChR and to characterize the restored light responses more fully. However, by providing an alternative method to deploy cell-population-specific optogenetics via proven AAV vectors, this represents a step toward clinical translation for cell-targeted melanopsin optogenetics. Given the demonstrated differences in other promoters specificity in degenerate retinas and when moving to primates, L7-6 appears to be particularly attractive and adds to a growing armory of retinal-cell-population-specific mini-promoters.

Comparing optogenetic targets and tools: Toward therapeutic optogenetics in IRDs
An overarching aim of this study was to functionally compare approaches to optogenetics in a retinal degeneration model, ultimately to help determine which tool, delivered by which approach, would best facilitate restoring naturalistic physiological responses to light. At the most basic level, such responses would ideally be large in amplitude, have fast kinetics, and be sensitive over a wide dynamic range. From the investigations described above, it could be concluded that there was no one combination that would meet all these criteria in this context. The remarkable diversity of electrophysiological responses to the same stimuli produced by targeting different optogenetic tools to different populations of retinal cells was particularly notable. For example, the diversity of spike firing responses demonstrated in Figures 2A and 3D are evocative of the diversity of native RGC-subtype responses (e.g., L7.ReaChR to sustained ON-type RGCs). As targeted optogenetics develops, the diversity of responses could indeed be a great advantage. An increased understanding of response characteristics of specific tools in specific cell populations could allow a calculated, multi-tool, multi-target approach. It could be envisioned that several tools, targeted to different retinal cell types, could replicate separate aspects of the wild-type retina’s diverse RGC spike firing responses or indeed a diversity of responses that plastic higher visual centers could learn to make use of, both of which could ultimately lead to a more naturalistic restored visual experience for the IRD patient.

CONCLUSION
Here, we describe the first direct comparison of optogenetic tools targeted to different subpopulations of surviving cells in a degenerate retina. The diversity of responses observed, and the clinically translatable delivery strategy described, hold great potential to improve the quality of optogenetic vision-restoration strategies for patients with IRDs.

MATERIALS AND METHODS
Mice
All experiments involving animals were performed in accordance with the Animals for Scientific Procedures Act 1986, licence numbers 30/3371 and PE4ED9D2C, and the University of Oxford policy on the use of animals in scientific research and in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision
Research. Animals were kept under a 12:12 h light/dark cycle, with food and water ad libitum.

Two transgenic lines were bred from predecessor lines (see Supplemental methods and Table S1) to produce mice homozygous for both the retinal degeneration causing mutation \textit{Pde6bd}\textsuperscript{fl}\textsuperscript{fr} and the knockout \textit{Oprn}\textsuperscript{fl}\textsuperscript{fr} allele\textsuperscript{30} while additionally expressing the Cre recombinase enzyme under the control of the ON-bipolar-cell-specific \textit{L7} promoter (alias \textit{Pcp2})\textsuperscript{11,82} or ganglion-cell-specific promoter \textit{Grik4}\textsuperscript{38,84} (see Supplemental methods and Table S2). The expected melanopsin-deficient, retinal-degenerate retinal phenotype was confirmed by IHC (Supplemental methods; Tables S3 and S4).

\section*{AAV vectors}

Three AAV vectors were produced following previously described methods\textsuperscript{13,84} to incorporate the hOPN4 and ReaChR constructs illustrated in Figures 1A, 1B, and 3A.\textsuperscript{6,85} In brief, HEK293T cells were co-transfected with these constructs, along with capsid (AAV2/2 quad mutant Y272,444,500,730F) and helper plasmids before cell lysis and purification using an iodixanol gradient and subsequent centrifugal concentration.\textsuperscript{13,84} Final purified virus was suspended in physiological concentration saline. Retinal expression of the expected proteins was confirmed by IHC (Supplemental methods).

\subsection*{L7-6 compressed promoter construct}

A compressed promoter construct \textit{L7-6},\textsuperscript{72} which has proven efficient in inducing cell-type-specific gene expression in cerebellar granule neurons but hitherto not examined in the retina, was kindly received from Prof. Hirai (Gunma University, Japan) and cloned into an AAV insert backbone along with the hOPN4 gene (Figure 4A) using an MluI/KpnI restriction enzyme approach. The resulting plasmid was used to produce AAV and was validated as described above.

\subsection*{Intraocular injections}

Bilateral intravitreal injections were administered to mice under isoflurane anesthesia at 6 to 8 weeks of age following previously published methods\textsuperscript{3,84} (Supplemental methods). \textit{L7.Cre} mice were injected with each of the three AAVs (Figures 1A and 3A) or saline (eight mice per group). \textit{Grik4.Cre} mice were injected with the two floxed viruses (flanked by \textit{LoxP}, i.e., requiring Cre recombinase within the target cell to be expressed) (Figures 1A and 3A) or saline (eight per group). Eight \textit{Pdeb6bd}\textsuperscript{fr}\textsuperscript{fr} \textit{Oprn}\textsuperscript{fl}\textsuperscript{fr}\textsuperscript{fr} \textit{L7.Cre} \textsuperscript{wt}\textsuperscript{fr}\textsuperscript{fr}\textsuperscript{fr} mice were injected with \textit{L7-6.hOPN4 AAV} (Figure 4A).

\subsection*{IHC}

IHC was performed following established in-house protocols\textsuperscript{13,84}. Briefly, directly after enucleation at 4–6 weeks post injection, eyes were transferred to 4% paraformaldehyde (PFA; Alfa Aesar, Ward Hill, MA, USA) for 24 h before cryoprotection with 30% sucrose-PBS for 48 h. Eyes were embedded in optimal cutting temperature (OCT) solution (Finetek, Torrance, CA, USA), and 20 \(\mu m\) sections were placed onto poly-lysine-coated slides (VWR, Leuven, Belgium). Permeabilisation with 0.2% Triton X–PBS (Sigma Aldrich, Gillingham, UK) was followed by blocking with 0.2% Triton X–PBS incorporating 10% serum from the animal in which the secondary antibody was raised (Table S4). Overnight primary antibody incubation was in 0.2% Triton-PBS X with 2.5% serum, followed by three 10 min washes in 0.1% Tween-PBS and overnight incubation with the secondary antibody at a concentration of 1:250 in 0.2% Triton X–PBS with 2.5% serum. Nuclei were stained with 300 nmol/L 4',6-Diamidino-2-Phenylindole (DAPI) (Thermo Fisher, Loughborough, UK) before mounting with ProLong Diamond mounting media (Thermo Fisher, Loughborough, UK). Retinal sections were visualized using a confocal microscope (LSM710; Zeiss, Oberkochen, Germany), and images were processed using Fiji-ImageJ.\textsuperscript{86} A similar method was used to stain flat mount retinas and is included in the supplemental methods. For each animal, four non-continuous 40× fields of view were selected from the flat mount as subjectively showing the highest levels of staining, and for each of these, the number of cells staining for hOPN4/GFP and the number only staining for DAPI were counted to give a proportion of stained cells.

\section*{MEA recordings}

Eight weeks following intraocular injections, mice were culled by cervical dislocation under dim red light (>610 nm). Dissected retinas were immediately transferred to glass-bottomed MEA chambers (Multi Channel Systems, Reutlingen, Germany) with a grid of 60, and 30 \(\mu m\) recording electrodes were spaced 200 \(\mu m\) apart and continuously perfused with Ames’ medium (Sigma Aldrich, Gillingham, UK) bubbled with 5\% CO\textsubscript{2} (pH 7.3) at 33\°C. Signals were amplified, digitized (at 25 kHz), recorded using the MC Rack software suite (Multichannel Systems, Reutlingen, Germany), and analyzed using a custom MS Excel spreadsheet (Supplemental materials). Retinas were equilibrated in the dark for 40 min before onset of experimental recordings (see Supplemental methods).

Light stimuli were produced by an X-cite 120W metal halide light source (Excitata, Southampton, UK) and conditioned by passing through spectral filters (480 ± 10 nm for hOPN4 groups or 510 ± 10 nm for ReaChR groups, corresponding to their respective \(\lambda_{max}\)) and neutral density filters to give one of seven intensities of light (10\textsuperscript{10} to 10\textsuperscript{16} photons cm\textsuperscript{2} s\textsuperscript{-1}) (all filters, Thorlabs, Ely, UK) (Supplemental material; Figure S1). The light pulses were delivered to the sample via a 10× objective (Olympus, Shinjuku, Japan) mounted to an inverted Zeiss I\texttimes71 microscope (Zeiss, Oberkochen, Germany). Stimuli were calibrated using an in-line power meter (Thor Labs, Ely, UK), and values were converted using a validated irradiance conversion toolbox.\textsuperscript{87}

Recordings began with 30 s of baseline recording before the onset of a 10 s light pulse. Recording was then continued until 90 s had elapsed. After each recording, an interval of 10 min was allowed for dark adaptation before the next trial.

\section*{Statistical analysis}

Analysis was carried out using Prism Software version 8.0 (GraphPad, San Diego, CA, USA). Significance was defined as \(p < 0.05\). Non-
normality was tested for using the Shapiro-Wilk and Kolmogorov-Smirnov tests. A one-way ANOVA was employed to compare a single variable across groups. With more than one variable, a two-way ANOVA with Tukey’s correction for multiple comparisons was used where data was normally distributed and the KW test with Dunn’s correction for multiple comparisons when it was not. Values are presented as mean ± standard error of mean.

SUPPLEMENTAL INFORMATION

Supplemental information can be found online at https://doi.org/10.1016/j.omtm.2022.03.003.

ACKNOWLEDGMENTS

The authors thank Prof. Hirai, Department of Neurophysiology & Neural Repair, Gunma University Graduate School of Medicine, Japan, for his kind gift of the L7-6 promoter construct and David Smithson, graphic designer, Department of Educational Media, University College London, for assistance with the graphical abstract. This work was supported by The Wellcome Trust (grant number 205151/Z/16/Z to M.J.G.), the Pro Retina Deutschland Foundation (grant number Pro-Re/Projekt/Gilhooley-Whitehead-Lindner.04-2021 to M.J.G. and M.L.), and the University Hospital Gießen and Marburg Research Funds (15/2020MR to M.L.) as well as the Biological Basic Sciences Research Council (grant number BB/M009998/1 to S.H., S.N.P., and M.W.H.). M.W.H. acknowledges the support of the Medical Research Council UK (MR/S026266/1). Preliminary findings from of this research were presented at the 2020 and 2021 annual meetings of the Association for Research in Vision and Ophthalmology (ARVO) and the 2020 and 2021 annual meetings of the North American Neuroophthalmology Society (NANOS).

AUTHOR CONTRIBUTIONS

M.J.G. planned and carried out experiments, analyzed data, and wrote and critically revised the manuscript. M.L. planned and carried out experiments, analyzed data, and wrote and critically reviewed the manuscript. T.P. carried out experiments and critically reviewed the manuscript. S.H. planned and carried out experiments and critically reviewed the manuscript. S.N.P. planned experiments and critically reviewed the manuscript. M.W.H. planned experiments and critically reviewed the manuscript.

DECLARATION OF INTERESTS

M.L. has received financial support from Heidelberg Engineering, Optos, and Genentech and is an equity owner of Fresenius Medical Care. The other authors declare no competing interests.

REFERENCES

1. Hartong, D.T., Berson, E.L., and Dryja, T.P. (2006). Retinitis pigmentosa. Lancet 368, 1795–1809.
2. Russell, S., Bennett, J., Wellman, J.A., Chung, D.C., Yu, Z.-F., Tillman, A., Wittes, J., Pappas, J., Elci, O., and McCague, S. (2017). Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet 390, 849–860.
3. Berry, M.H., Holt, A., Salari, A., Velt, J., Visel, M., Levitz, I., Aghi, K., Gaub, B.M., Sivyer, B., Flannery, J.G., et al. (2019). Restoration of high-sensitivity and adapting vision with a cone opsin. Nat. Commun. 10, 1221.
4. Bi, A., Cui, J., Ma, Y.-P., Olshhevskaya, E., Pu, M., Diehoor, A.M., and Pan, Z.-H. (2006). Ectopic expression of a microbial-type rhodopsin restores visual responses in mice with photoreceptor degeneration. Neuron 50, 23–33.
5. Cehajic-Kapetanovic, J., Eleftheriou, C., Allen, A.E., Milosavljevic, N., Pinaev, A., Bedford, R., Davis, K.E., Bishop, P.N., and Lucas, R.J. (2015). Restoration of vision with ectopic expression of human rod opsins. Curr. Biol. 25, 2111–2122.
6. De Silva, S.R., Barnard, A.R., Hughes, S., Tam, S.K.E., Martin, C., Singh, M.S., Barnes-Cramer, A.O., McClements, M.E., During, M.J., Peirson, S.N., et al. (2017). Long-term restoration of visual function in end-stage retinal degeneration using subretinal human melanopsin gene therapy. Proc. Natl Acad. Sci. U S A 114, 11211–11216.
7. Gajiwala, T.H., Lu, Q., Fenner, M.D., Abrams, G.W., and Pan, Z.-H. (2019). Improved channelrhodopsin variants restore visual acuity and contrast sensitivity in A mouse model of blindness under ambient light conditions. Mol. Ther. 27, 1195–1205.
8. Gaub, B.M., Berry, M.H., Holt, A.E., Isacoff, E.Y., and Flannery, J.G. (2015). Optogenetic vision restoration using rhodopsin for enhanced sensitivity. Mol. Ther. 23, 1562–1571.
9. Liu, M.M., Dai, J.M., Liu, W.Y., Zhao, C.J., Lin, B., and Yin, Z.Q. (2016). Human melanopsin-AAV2/8 transplantation to retina transiently restores visual function in rd1 mice. Int. J. Ophthalmol. 9, 655–661.
10. Sengupta, A., Chaffiol, A., Macé, E., Caplette, R., Desrosiers, M., Lampic, M., Forster, V., Marre, O., Lin, J.Y., and Sahel, J.A. (2016). Red-shifted channelrhodopsin stimulation restores light responses in blind mice, macaque retina, and human retina. EMBO Mol. Med. 8, 1248–1264.
11. Thiyagarajan, S., van Wyk, M., Lehmann, K.,Lowell, S., Feng, G., and Wissel, H. (2010). Visual function in mice with photoreceptor degeneration and transgenic expression of channelrhodopsin 2 in ganglion cells. J. Neurosci. 30, 8745–8758.
12. van Wyk, M., Pielecka-Fortuna, J., Lowell, S., and Kleinlogel, S. (2015). Restoring the ON switch in blind retina: opto-mGluR6, a next-generation, cell-tailored optogenetic tool. PLoS Biol. 13, e1002143.
13. Lindner, M., Gilhooley, M.J., Peirson, S.N., Hughes, S., and Hankins, M.W. (2020). The functional characteristics of optogenetic gene therapy for vision restoration. Cell Mol. Life Sci. 77, 1597–1613.
14. Lu, Q., and Pan, Z.-H. (2021). Optogenetic strategies for vision restoration. In: Optogenetics: Light-Sensing Proteins and Their Applications in Neuroscience and beyond. H. Yawo, H. Kandori, A. Kozumi, and R. Kageyama, eds. (Springer Singapore), pp. 545–555.
15. Simon, C.J., Sahel, J.A., Dueld, J., Herlitze, S., and Dalkara, D. (2020). Opsins for vision restoration. Biochem. Biophys. Res. Commun. 527, 325–330.
16. Sahel, J.A., Boulanger-Sceama, E., Pagot, C., Arleo, A., Galluppi, F., Martel, J.N., Esposti, S.D., Delaux, A., de Saint Aubert, J.B., de Montleau, C., et al. (2021). Partial recovery of visual function in a blind patient after optogenetic therapy. Nat. Med. 27, 1223–1229.
17. Macé, E., Caplette, R., Marre, O., Sengupta, A., Chaffiol, A., Barbe, P., Desrosiers, M., Bamberg, E., Sahel, J.-A., and Picaud, S. (2015). Targeting channelrhodopsin 2 to ON-bipolar cells with vitreally administered AAV Restores ON and OFF visual responses in blind mice. Mol. Ther. 23, 7–16.
18. Labal, P., Balya, D., Awatramani, G.B., Munich, T.A., Kim, D.S., Buskamp, V., Cepko, C.L., and Roska, B. (2008). Light-activated channels targeted to ON bipolar cells restore visual function in retinal degeneration. Nat. Neurosci. 11, 667–675.
19. Gaub, B.M., Berry, M.H., Holt, A.E., Reiner, A., Kienzler, M.A., Dolgova, N., Nikonov, S., Aguirre, G.D., Beltran, W.A., Flannery, J.G., et al. (2014). Restoration of visual function by expression of a light-gated mammalian ion channel in retinal ganglion cells or ON-bipolar cells. Proc. Natl Acad. Sci. U S A 111, E5574–E5583.
20. Lin, B., Kozumi, A., Tanaka, N., Panda, S., and Masland, R.H. (2008). Restoration of visual function in retinal degeneration mice by ectopic expression of melanopsin. Proc. Natl Acad. Sci. U S A 105, 16009–16014.
21. Liu, W., Liu, M., Liu, Y., Li, S., Weng, C., Fu, Y., He, J., Gong, Y., Liu, W., Zhao, C., et al. (2018). Validation and Safety of visual restoration by ectopic expression of human melanopsin in retinal ganglion cells. Hum. Gene Ther. 36, 714–726.
22. Lu, Q., Ganjwala, T.H., Hattar, S., Abrams, G.W., and Pan, Z.H. (2018). A robust optomotor assay for assessing the efficacy of optogenetic tools for vision restoration. Invest. Ophthalmol. Vis. Sci. 59, 1288–1294.

23. Lu, Q., Ganjwala, T.H., Krstevski, A., Abrams, G.W., and Pan, Z.H. (2020). Comparison of AAV-mediated optogenetic vision restoration between retinal ganglion cell expression and ON bipolar cell targeting. Mol. Ther. Methods Clin. Dev. 18, 15–23.

24. Hughes, S., Rodgers, J., Hickey, D., Foster, R.G., Peirson, S.N., and Hinks, M.W. (2016). Characterisation of light responses in the retina of mice lacking principle components of rod, cone and melanopsin phototransduction signalling pathways. Sci. Rep. 6, 28086.

25. Qiu, X., Kumbalasiri, T., Carlson, S.M., Wong, K.Y., Krishna, V., Provenzio, L., and Berner, D.M. (2005). Induction of photosensitivity by heterologous expression of melanopsin. Nature 433, 745–749.

26. Palumaa, T., Gilhooley, M.J., Jagannath, A., Hinks, M.W., Hughes, S., and Peirson, S.N. (2018). Melanopsin: photoreceptors, physiology and potential. Curr. Opin. Physiol. 5, 68–74.

27. Ivanova, E., Lee, P., and Pan, Z.H. (2013). Characterisation of multiple bistratified retinal ganglion cells in a purkinje cell protein 2-Cre transgenic mouse line. J. Comp. Neurol. 521, 2165–2180.

28. Ivanova, E., Hwang, G.S., and Pan, Z.H. (2010). Characterisation of transgenic mouse lines expressing Cre recombinase in the retina. Neuroscience 165, 233–243.

29. Kleinlogel, S., Vogl, C., Jeschke, M., Neef, J., and Moser, T. (2020). Emerging approaches for restoration of hearing and vision. Physiol. Rev. 100, 1467–1525.

30. Hulliger, E.C., Hostettler, S.M., and Kleinlogel, S. (2020). Empowering retinal gene therapy with a specific promoter for human rod and cone ON-bipolar cells. Mol. Ther. Methods Clin. Dev. 17, 505–519.

31. Wu, Z., Yang, H., and Colosi, P. (2010). Effect of genome size on AAV vector packaging. Mol. Ther. 18, 80–86.

32. Nitta, K., Matsuizaki, Y., Konno, A., and Hirai, H. (2017). Minimal purkinje cell-specific Pcp2/L7 promoter virally available for rodents and non-human primates. Mol. Ther. Methods Clin. Dev. 6, 159–170.

33. Bailes, H.J., and Lucas, R.J. (2013). Human melanopsin forms a pigment maximally sensitive to blue light (λmax approximately 479 nm) supporting activation of G(q/11) and G(i/o) signalling cascades. Proc. Biol. Sci. 280, 20122987.

34. Sposida, K., Eckelbeck, D., Karapinar, R., Eckhardt, T., Mark, M.D., Jancke, D., Ehinger, R.V., Konig, P., Dalkara, D., Hertlitze, S., et al. (2016). Melanopsin variants as intrinsic opticogenetic on and off switches for transient versus sustained activation of G protein pathways. Curr. Biol. 26, 1206–1212.

35. Hughes, S., Jagannath, A., Hickey, D., Gatti, S., Wood, M., Peirson, S.N., Foster, R.G., and Hinks, M.W. (2015). Using siRNA to define functional interactions between melanopsin and multiple G Protein partners. Cell Mol. Life Sci. 72, 165–179.

36. Hughes, S., Hinks, M.W., Foster, R.G., and Peirson, S.N. (2012). Melanopsin phototransduction: slowly emerging from the dark. Prog. Brain Res. 199, 19–40.

37. Jiang, Z., Yue, W.W.S., Chen, L., Sheng, Y., and Yau, K.-W. (2018). Cyclic-nucleotide-gated channelrhodopsin-2 safely and effectively restores visual function in multiple mouse models of blindness. Mol. Ther. 26, 1343–1345.

38. Juttner, I., Szabo, A., Gross-Scherf, B., Morikawa, R.K., Rompani, S.B., Hantz, P., Sztika, T., Esposti, F., Cowan, C.S., Bharioke, A., et al. (2019). Targeting neuronal and glial cell types with synthetic promoter AAVs in mice, non-human primates and humans. Nat. Neurosci. 22, 1345–1356.

39. van Wyk, M., Hulliger, E.C., Girod, L., Ebner, A., and Kleinlogel, S. (2017). Present molecular limitations of ON-bipolar cell targeted gene therapy. Front. Neurosci. 11, 161.

40. Doroudchi, M.M., Greenberg, K.P., Liu, J., Silka, K.A., Boydens, E.S., Leckridge, J.A., Arman, A.C., Janani, R., Boye, S.E., Boye, S.L., et al. (2011). Virally delivered channelrhodopsin-2 safely and effectively restores visual function in multiple mouse models of blindness. Mol. Ther. 19, 1220–1229.

41. Cronin, T., Vandenbergh, L.H., Hantz, P., Juttner, J., Reimann, A., Kacso, A.E., Huckfeldt, R.M., Busskamp, V., Kohler, H., Lagali, P.S., et al. (2014). Efficient光分散性をもつネズミの投与後3日目のリッピクスによる効果的な視覚修復。J. Comp. Neurol. 521, 6051–6058.

42. Haverkamp, S., and Wässle, H. (2000). Immunocytochemical analysis of the mouse retina. Invest. Ophthalmol. Vis. Sci. 41, 1009–1018.

43. Cameron, E.G., and Robinson, P.R. (2014). β-Arrestin-dependent deactivation of mouse melanopsin. PLoS One 9, e113138.

44. Mure, L.S., Hatori, M., Ruda, K., Benegiamo, G., Demas, J., and Panda, S. (2018). Sustained melanopsin photosresponse is supported by specific roles of beta-arrestin 1 and 2 in deactivation and regeneration of photopigment. Cell Rep. 25, 2497–2509.e4.

45. Panda, S., Nayak, S.K., Campo, B., Walker, J.R., Hogenesch, J.B., and Jegla, T. (2005). Illumination of the melanopsin signaling pathway. Science 307, 600–604.
transduction and optogenetic stimulation of retinal bipolar cells by a synthetic adenovirus capsid and promoter. EMBO Mol. Med. 6, 1175–1190.

64. Gilbooley, M.J., Hickey, D.G., Lindner, M., Palumaa, T., Hughes, S., Peirson, S.N., MacLaren, R.E., and Hankins, M.W. (2021). ON-bipolar cell gene expression during retinal degeneration: implications for optogenetic visual restoration. Exp. Eye Res. 207, 108553.

65. Jones, B.W., and Marc, R.E. (2005). Retinal remodeling during retinal degeneration. Exp. Eye Res. 81, 123–137.

66. Marc, R.E., Jones, B.W., Watt, C.B., and Strettoi, E. (2003). Neural remodeling in inherited photoreceptor degenerations. Mol. Neurobiol. 28, 139–147.

67. Kalloniatis, M., Nivison-Smith, L., Chua, J., Acosta, M.L., and Fletcher, E.L. (2016). Using the rd1 mouse to understand functional and anatomical retinal remodelling and treatment implications in retinitis pigmentosa: a review. Exp. Eye Res. 150, 106–121.

68. Marc, R.E., and Jones, B.W. (2003). Retinal remodeling in inherited photoreceptor degenerations. Mol. Neurobiol. 28, 139–147.

69. Marc, R.E., Jones, B.W., Anderson, J.R., Kinard, K., Marshak, D.W., Wilson, J.H., Wensel, T., and Lucas, R.J. (2007). Neural reprogramming in retinal degeneration. Invest. Ophthalmol. Vis. Sci. 48, 3364–3371.

70. Varela, C., Igarzua, J., De la Rosa, E.L., and De la Villa, P. (2003). Functional modifications in rod bipolar cells in a mouse model of retinitis pigmentosa. Vis. Res. 43, 879–885.

71. Dunn, F.A. (2015). Photoreceptor ablation initiates the immediate loss of glutamate receptors in postsynaptic bipolar cells in retina. J. Neurosci. 35, 2423–2431.

72. Gayet-Primo, J., and Puthussery, T. (2015). Alterations in Kainate receptor and TRPM1 localization in bipolar cells after retinal photoreceptor degeneration. Front. Cell Neurosci. 9, 486.

73. Korecki, A.J., Cueva-Vargas, J.L., Fornes, O., Agostinone, J., Farkas, R.A., Hickmott, J.W., Lam, S.L., Mathelier, A., Zhou, M., Wasserman, W.W., et al. (2021). Human MiniPromoters for ocular-rAAV expression in ON bipolar, cone, corneal, endothelial, Muller glial, and PAX6 cells. Gene Ther. 28, 351–372.

74. de Leeuw, C.N., Korecki, A.J., Berry, G.E., Hickmott, J.W., Lam, S.L., Lengyell, T.C., Bonaguro, R.J., Borretta, L.J., Chopra, V., Chou, A.Y., et al. (2016). rAAV-compatible MiniPromoters for restricted expression in the brain and eye. Mol. Brain 9, 52.

75. de Leeuw, C.N., Dyka, F.M., Boye, S.L., Laprise, S., Zhou, M., Chou, A.Y., Borretta, L., McNerny, S.C., Banks, K.G., Portales-Casamar, E., et al. (2014). Targeted CNS delivery using human MiniPromoters and demonstrated compatibility with adeno-associated viral vectors. Mol. Ther. Methods Clin. Dev. 1, 5.

76. Portales-Casamar, E., Swanson, D.J., Liu, L., de Leeuw, C.N., Banks, K.G., Ho Sui, S.I., Fulton, D.L., Ali, J., Amirabbasi, M., Arenillas, D.J., et al. (2010). A regulatory toolbox of MiniPromoters to drive selective expression in the brain. Proc. Natl. Acad. Sci. U.S.A 107, 16589–16594.

77. Lu, Q., Ganjawala, T.H., Ivanova, E., Cheng, J.G., Troilo, D., and Pan, Z.H. (2016). AAV-mediated transduction and targeting of retinal bipolar cells with improved nGluR6 promoters in rodents and primates. Gene Ther. 23, 680–689.

78. Baden, T., Berens, P., Franke, K., Roman Roson, M., Bethge, M., and Euler, T. (2016). The functional diversity of retinal ganglion cells in the mouse. Nature 529, 345–350.

79. Bowes, C., Li, T., Danciger, M., Baxter, L.C., Applebury, M.L., and Farber, D.B. (1990). Retinal degeneration in the rd mouse is caused by a defect in the β subunit of rod cGMP-phosphodiesterase. Nature 347, 677.

80. Hattar, S., Liao, H.W., Takaö, M., Berson, D.M., and Yau, K.W. (2002). Melanopsin-containing retinal ganglion cells: architecture, projections, and intrinsic photosensitivity. Science 295, 1065–1070.

81. Silva Marino, P.K., Leung, C., Hetty, A., van der Korput, G.M., Jan, T., Camenisch, I., Berna, A., and Brandner, S. (2002). PTEN is essential for cell migration but not for fate determination and tumourigenesis in the cerebellum. Development 129, 3513–3522.

82. Lu, Q., Ivanova, E., Ganjawala, T.H., and Pan, Z.H. (2013). Cre-mediated recombination efficiency and transgene expression patterns of three retinal bipolar cell-expressing Cre transgenic mouse lines. Mol. Vis. 19, 1310–1320.

83. Nakazawa, K., Quirk, M.C., Chitwood, R.A., Watanabe, M., Yekel, M.F., Sun, I.D., Kato, A., Carr, C.A., Johnston, D., and Wilson, M.A. (2002). Requirement for hippocampal CA3 NMDA receptors in associative memory recall. Science 297, 211–218.

84. de Silva, S.R., McClements, M.E., Hankins, M.W., and MacLaren, R.E. (2015). Adeno-associated viral gene therapy for retinal disorders. Gene Deliv. Ther. Neurol. Disord. 203–228.

85. Lin, Y.J., Knutsen, P.M., Muller, A., Kleinfeld, D., and Tien, R.Y. (2013). ReaChR: a red-shifted variant of channelrhodopsin enables deep transcranial optogenetic excitation. Nat. Neurosci. 16, 1499–1508.

86. Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., Preibisch, S., Rueden, C., Saalfeld, S., and Schmid, B. (2012). Fiji: an open-source platform for biological-image analysis. Nat. Methods 9, 676.

87. Lucas, R.J., Peirson, S.N., Berson, D.M., Brown, T.M., Cooper, H.M., Creider, C.A., et al. (2014). Measuring and using light in the melanopsin age. Trends Neurosci. 37, 1–9.